Radiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast (BIG 3–07/TROG 07 01): a randomised, factorial, multicentre, open-label, phase 3 study
thelancet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thelancet.com Daily Mail and Mail on Sunday newspapers.
Mortality trends over five decades in adult transgender people receiving hormone treatment: a report from the Amsterdam cohort of gender dysphoria
thelancet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thelancet.com Daily Mail and Mail on Sunday newspapers.
APSHO Supports Full Scope-of-Practice Regulation for Advanced Practitioners in Open Letter to President Biden
Share Article
The Advanced Practitioner Society for Hematology and Oncology (APSHO), a society of nurse practitioners, physician assistants, pharmacists, and other health-care providers, encourages the administration to remove unnecessary practice barriers and expand patient access to health-care services. LAWRENCEVILLE, N.J. (PRWEB) April 21, 2021
The Advanced Practitioner Society for Hematology and Oncology (APSHO) sent an open letter to President Biden requesting support for regulatory changes that authorize advanced practitioners and other health professionals to practice to the full extent of their education, clinical competence, and experience during the COVID-19 pandemic.
Share this article
Share this article
SHANGHAI, Jan. 6, 2021 /PRNewswire/ Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China and other parts of Asia, announced today that it has initiated the submission of a New Drug Application (NDA) to the Health Sciences Authority (HSA) of Singapore for sacituzumab govitecan-hziy for the treatment of patients with metastatic triple-negative breast cancer (mTNBC) who have received at least two prior therapies for metastatic disease. Breast Cancer is Singapore s number one leading cause of cancer death in women and TNBC accounts for 15-20% of all breast cancer in Singapore. This milestone marks the first of a series of planned NDA submissions for sacituzumab govitecan-hziy in Everest s licensed territory, which also includes Greater China, South Korea, and certain additional South